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XBP1 splicing triggers miR-150 
transfer from smooth muscle cells 
to endothelial cells via extracellular 
vesicles
Yue Zhao1,2,*, Yi Li2,*, Peiyi Luo2, Yingtang Gao3, Junyao Yang2, Ka-Hou Lao2, Gang Wang4, 
Gillian Cockerill5, Yanhua Hu2, Qingbo Xu2, Tong Li1,3 & Lingfang Zeng2
The interaction between endothelial cells (ECs) and smooth muscle cells (SMCs) plays a critical role in 
the maintenance of vessel wall homeostasis. The X-box binding protein 1 (XBP1) plays an important 
role in EC and SMC cellular functions. However, whether XBP1 is involved in EC-SMC interaction 
remains unclear. In this study, In vivo experiments with hindlimb ischemia models revealed that XBP1 
deficiency in SMCs significantly attenuated angiogenesis in ischemic tissues, therefore retarded the 
foot blood perfusion recovery. In vitro studies indicated that either overexpression of the spliced XBP1 
or treatment with platelet derived growth factor-BB up-regulated miR-150 expression and secretion 
via extracellular vesicles (EVs). The XBP1 splicing-mediated up-regulation of miR-150 might be due to 
increased stability. The SMC-derived EVs could trigger EC migration, which was abolished by miR-150 
knockdown in SMCs, suggesting miR-150 is responsible for SMC-stimulated EC migration. The SMC-
derived miR-150-containing EVs or premiR-150 transfection increased vascular endothelial growth 
factor (VEGF)-A mRNA and secretion in ECs. Both inhibitors SU5416 and LY294002 attenuated EVs-
induced EC migration. This study demonstrates that XBP1 splicing in SMCs can control EC migration 
via SMC derived EVs-mediated miR-150 transfer and miR-150-driven VEGF-A/VEGFR/PI3K/Akt pathway 
activation, thereby modulating the maintenance of vessel wall homeostasis.
Endothelial cells (ECs) and smooth muscle cells (SMCs) are two major cellular components within the vessel 
wall. ECs line the lumen forming an intact mono-layered structure that provides a semi-selective barrier between 
blood and the underlying tissues, and modulating vessel tone via nitric oxide production. SMCs are responsible 
for the contractility of the vessel wall. The liaison between ECs and SMCs plays an essential role in vessel matu-
ration under physiological conditions, vascular injury repair and disease development such as atherosclerosis1,2.
MicroRNAs (miRNAs, miRs) are a set of small non-coding RNAs that participate in multiple cellular processes 
through regulating gene transcription, mRNA stability and protein translation3. Recent studies have revealed that 
miRNAs can be released from cells, delivered by extracellular vesicles(EVs) and act on recipient cells in a parac-
rine way, modulating intercellular communications4–8. The miR-150 family is located in human chromosome 19. 
MiR-150 has been shown to participate in multiple physiological and pathological processes, including hemato-
poietic cell differentiation9,10 and suppresses tumour cells proliferation11,12. In cardiovascular system, miR-150 is 
reported to promote endothelial progenitor cells homing13 and monocyte-EC interaction14, while it may also be 
involved in the pathogenesis of pulmonary arterial hypertension15,16. In our previous study, we noticed that series 
of microRNA levels including miR-150 in SMCs were up-regulated during the neointimal formation after vascu-
lar injury17. However, the potential role of miR-150 in EC-SMC communication remains unclear.
The X-box binding protein 1 (XBP1) was originally identified as a stress-inducible transcription factor essen-
tial for cell survival under stress conditions18–20. Under endoplasmic reticulum (ER) stress conditions, XBP1 
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mRNA undergoes unconventional splicing through an ER-resident kinase that possesses ribonuclease activity, 
the inositol requiring enzyme 1 alpha (IRE1α)21. Our recent studies and reports from other groups showed that 
physiological stimuli like vascular endothelial cell growth factor (VEGF) could trigger XBP1 splicing in an ER 
stress response independent manner22–25. In ECs, XBP1 splicing plays diverse roles including cell proliferation23, 
autophagy response26 and apoptosis27. In SMCs, BMP-2 was reported to activate XBP1 splicing28. Our study 
revealed that XBP1 splicing was activated in vascular SMCs in response to vascular injury in vivo and platelet 
derived growth factor-BB (PDGF-BB) stimulation in vitro and that XBP1 deficiency in SMCs attenuated neoin-
tima formation in mouse model of femoral artery injury17. In this study, we demonstrated that XBP1 splicing in 
SMC regulated EC migration via EVs-mediated miR-150 transfer.
Results
XBP1 deficiency in SMCs attenuated the foot blood perfusion recovery in mouse hindlimb 
ischemia model. To test whether XBP1 was involved in EC-SMC interaction, we performed a hindlimb 
ischemia model in SM22-Cre/XBP1loxP/loxP (XBP1smcko) mice and observed foot blood perfusion recovery. 
Compared to XBP1loxP/loxP mice, the foot blood perfusion recovery in the injured limb was significantly attenuated 
in mice at 2 weeks post-surgery (Fig. 1A) as revealed by Doppler scanning analysis. Immunofluorescence staining 
with anti-CD31 and anti-α SMA antibodies revealed that the capillary vessel density was significantly decreased in 
the injured skeletal muscle in XBP1smcko mice as compared to XBP1loxP/loxP mice (Fig. 1B). These results suggest 
XBP1 deficiency in SMCs may affect angiogenesis, therefore causing the retardation of the foot blood perfusion 
recovery.
Figure 1. Disruption of XBP1 gene in SMCs decreased angiogenesis in ischemic tissue. The right femoral 
arteries were banded at two adjacent sites with internal part cut to totally block foot blood supply in XBP1loxP/loxP 
(WT, n = 7) or SM22-Cre+/XBP1loxP/loxP (XBP1smcko, n = 21) mice. The blood flow (A) at both sides was measured 
by Doppler Laser Scanner at 30 minutes, 7 days and 14 days post-surgery. After blood flow measurement, the 
mice were humanely sacrificed and the skeletal muscle tissues around the banding site were harvested and 
subjected to cryo-sectioning and double immunostaining with anti-CD31 (red) and anti-SMA (green) antibodies 
(B). (A) Left panel shows the representative images from one mouse of each group at 14 days post-surgery. 
The white open box indicates the blood flow data collecting area. The right panel shows the average blood 
flow perfusion ratio of the right to the left foot from all mice in each group. (mean ± SEM, * P < 0.05; ANOVA, 
Dunnett post-test). (B) Left panel shows the representative images of blood vessels in the skeletal muscle tissues 
from one mouse of each group at 14 days post-surgery. Nucleus was conterstained with DAPI. Scale bar: 100 μ m. 
Right panel shows the average vessel density (all vessels including capillary vessels) in the tissues collected from 
all mice in each group. (mean ± SEM, * P < 0.05; Student T-test).
www.nature.com/scientificreports/
3Scientific RepoRts | 6:28627 | DOI: 10.1038/srep28627
Overexpression of XBP1s in SMCs triggered EC migration via paracrine mechanisms. During 
the angiogenesis process, the initial step is the migration of ECs out of the intact endothelium, followed by EC 
proliferation. As described above, XBP1 deficiency in SMC affected angiogenesis in ischemic tissue, indicating 
that XBP1 in SMC may be involved in EC migration and proliferation via a paracrine mechanism. To test this, 
the conditioned medium was collected from SMCs infected with Ad-XBP1u and Ad-XBP1s viruses respectively, 
and applied to HUVECs to assess cell proliferation and migration. Cell number calculation assays showed that 
there was no difference among the conditioned media from SMCs infected with either of the two viruses or the 
control virus (Ad-null) (Fig. 2A), suggesting that XBP1 in SMC has no effect on EC proliferation. There was 
a decrease of cell proliferation under conditioned media as compared to fresh medium, which might be due 
to prior nutrient consumption by SMCs in the conditioned media. However, the EC monolayer wound heal-
ing assay revealed that the conditioned medium from SMCs infected with Ad-XBP1s, but not those from cells 
infected with Ad-XBP1u-infected, had significantly increased EC migration (Fig. 2B). This was further confirmed 
by transwell-based migration assay (Fig. 2C), suggesting that XBP1 splicing in SMCs may regulate EC migration 
through some secreted factors.
MiR-150 was mediated by overexpression of XBP1s in SMCs-induced EC migration. To analyse 
the potential responsible factors in the conditioned medium, EVs was isolated by ultracentrifugation. The effect 
of the whole conditioned medium, EVs and EVs-depleted medium on EC migration was performed with the 
transwell migration assay. As shown in Fig. 3A, both EVs and EVs-depleted medium from Ad-XBP1s-infected 
SMCs significantly increased EC migration, suggesting that stimulating factors exist in both EVs and medium. 
In our previous study, we found that activation of XBP1 splicing modulated multiple microRNA levels in SMCs, 
of which miR-150 was up-regulated17. It has been reported that miR-150 was involved in monocyte-regulated 
EC migration14,29. Therefore, we wondered whether miR-150 contributed to EVs-mediated pro-migratory effect. 
Quantitative RT-PCR analysis confirmed that overexpression of XBP1s in SMCs increased cellular and EVs miR-
150 levels (Fig. 3B). Transfection of SMCs with anti-miR-150 oligos abolished overexpression of XBP1s-mediated 
upregulation of miR-150 in both whole cell lysates and EVs (Fig. 3C). As expected, the anti-miR-150 transfection 
in SMCs abolished the EC pro-migratory effect of the EVs isolated from Ad-XBP1s-infected SMCs as compared 
to control anti-mir RNA oligos (Fig. 3D). Tube formation is another criterion to evaluate EC functions in angio-
genesis. Our studies revealed that EVs isolated from Ad-XBP1s-infected HSMCs significantly increased HUVEC 
capillary structure formation on Matrigel, which was ablated by anti-miR-150 transfection in SMCs (Fig. 3E). 
These results suggest that miR-150 plays an essential role in EVs-mediated EC migration and angiogenesis.
PDGF upregulated miR-150 in SMCs in XBP1 splicing dependent manner. To test whether miR-
150 could be upregulated in SMCs under physiological or pathological conditions, the effect of PDGF has been 
Figure 2. XBP1 splicing in SMCs increased EC migration via secreted factors. HSMCs were infected with 
Ad-null (null), Ad-XBP1s (1s), or Ad-XBP1u (1u) at 10 MOI for 24 hr. The medium was then replaced by M199 
medium supplemented with 0.5% FBS and incubated for 8 hr. The conditioned medium was then applied 
to HUVECs for proliferation assays via cell number counting (A) 24 hr post incubation) and cell migration 
assessments via wound healing assays (B) 6 hr post incubation, scale bar: 200 μ m) and transwell migration 
assays (C) 6 hr post incubation, scale bar: 25 μ m). Data presented are representative images or mean ± SEM of 
three independent experiments. (* P < 0.05; ANOVA, Dunnett post-test).
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examined. Our previous studies have revealed that PDGF treatment triggered XBP1 splicing via IRE1α phospho-
rylation17. Hence SMCs were infected with IRE1α or XBP1 shRNA lentivirus and treated with PDGF, followed 
by analysis of miR-150 in whole cell lysate and EVs. As shown in Fig. 4A, PDGF treatment increased miR-150 
in both the cell lysate and EVs from non-target shRNA (NTsh) infected SMCs. However, the increase was abol-
ished by either IRE1α shRNA (IRE1αsh) or XBP1 shRNA (XBP1sh). These results suggest that IRE1α-mediated 
XBP1 splicing is essential for PDGF-induced miR-150 upregulation and secretion via EVs. The EVs isolated from 
PDGF-treated SMCs increased EC migration, which was abolished by anti-miR-150 transfection (Fig. 4B), sug-
gesting that miR-150 is involved in PDGF-mediated EC/SMC interaction.
XBP1s increased miR-150 stabilization. XBP1 is a zinc leucine zip transcription factor. Our previous 
study has shown that XBP1 splicing in SMCs increased mir-1274B via direct transcriptional regulation17. We 
wondered whether a similar mechanism exists in miR-150 upregulation. To test this, we cloned a 1.1 kb frag-
ment corresponding to the promoter region of the miR-150 gene into pSI-Check2 vector to replace the SV40 
early enhancer promoter. Co-transfection of this plasmid with XBP1s overexpressing plasmid (pShuttle2-XBP1s 
(pXBP1s)) was performed in SMCs, followed by luciferase activity assays. Surprisingly, overexpression of XBP1s 
did not increase the reporter gene expression, but instead decreased the reporter gene expression (Fig. 5A). 
Chromatin-immunoprecipitation assay did not show a direct binding of XBP1s to the promoter region(data not 
shown). Therefore, we assumed that XBP1s increased miR-150 stability, leading to feedback inhibitory effect on its 
transcription. Indeed, when the reporter plasmid was co-transfected with miR-150 pre-mir mimic, the reporter 
gene expression was significantly decreased (Fig. 5B), suggesting a feedback inhibitory effect exists.
MiR-150 activated VEGF-A autocrine/paracrine-mediated VEGF receptor/PI3K-Akt signalling 
pathway. It was reported that microvesicle-derived miR-150 could promote tumorigenesis via up-regulating 
Figure 3. miR-150 was mediated by XBP1 splicing in SMC-induced EC migration. (A) Effect of the 
whole conditioned medium (W), EVs and supernatant (S) on HUVEC migration in transwell assay. (B) 
Over-expression of XBP1s in SMC increased miR-150 expression and secretion in EVs. (C) anti-miR-150 
abolished XBP1s-induced miR-150 expression and secretion. (D) anti-miR-150 abolished XBP1s/SMC-derived 
EVs-induced HUVEC migration. Data presented are mean ± SEM of three independent experiments. (E) 
anti-miR-150 abolished XBP1s/SMC-derived EVs-induced HUVEC tube formation. Left panel shows the 
representative images. Right panel shows the average tubes/10x view from 3 views/well of 3 wells (* P < 0.05; 
ANOVA, Dunnett post-test).
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VEGF30. VEGF is a well-known EC activator, modulating multiple EC functions including migration. Thus, 
we wondered whether there was a crosstalk between miR-150 and VEGF in our system. We firstly assessed the 
effect of Ad-XBP1s/HSMC-derived EVs on the VEGF-A mRNA in HUVECs and found that the EVs transiently 
upregulated VEGF-A mRNA level (Fig. 6A). Western blot analysis revealed that Ad-XBP1s/HSMC-derived EVs 
exerted different effect on two VEGF/VEGF receptor downstream signal pathways, ErK and Akt pathways. The 
EVs increased Akt phosphorylation but decreased ErK phosphorylation (Fig. 6B). Knockdown of miR-150 by 
anti-miR-150 transfection in HSMCs abolished XBP1s/HSMC-derived EVs-induced VEGF-A mRNA upregula-
tion (Fig. 6C) and Akt phosphorylation (Fig. 6D), suggesting that EVs-mediated VEGF-A upregulation and Akt 
phosphorylation is miR-150 dependent. VEGF receptor inhibitor SU5416 abolished EV-induced Akt phospho-
rylation in HUVECs (Fig. 6E), suggesting that VEGF-A may function as an autocrine or paracrine factor for Akt 
activation. Further experiments demonstrated that SU5416 and PI3K inhibitor LY294002 significantly decreased 
Figure 4. PDGF up-regulated miR-150 expression and secretion in SMC in IRE1α/XBP1 dependent 
manner. (A) PDGF increased miR-150 expression and secretion in SMC in an XBP1 splicing dependent 
manner. HSMCs were infected with non-target (NTsh), IRE1α (Ish) or XBP1 (Xsh) shRNA lentivirus at 100 
IU for 48 hr, and then treated with DMEM supplemented with 0.5% FBS for 24 hr, followed by 20 ng/ml 
PDGF-BB treatment for 4 hr. The cellular and EV miR-150 levels were assessed by quantitative RT-PCR of 
three independent experiments. (mean ± SEM, * P < 0.05; ANOVA, Dunnett post-test) (B) The anti-miR-150 
abolished PDGF/SMC-mediated EC migration. HSMCs was transfected with anti-miR-150 RNA (anti) and 
incubated in complete growth medium for 48 hrs, and then treated with 0.5% FBS medium for 24 hr, followed 
by 20 ng/ml PDGF-BB treatment for 4 hr. The effect of isolated EVs on HUVEC migration was assessed by 
transwell migration assays. The left panel shows the representative images, while the right panel shows the 
statistical analysis of migrated cells per 10x view. Control anti-miR RNA (ctl) was included. Scale bar: 25 μ m.  
Data presented are representative images or mean ± SEM of three independent experiments. (* P < 0.05; 
ANOVA, Dunnett post-test).
www.nature.com/scientificreports/
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Ad-XBP1s/HSMC-derived EVs-induced EC migration as revealed by transwell migration assays (Fig. 6F). These 
results suggest that miR-150-mediated VEGF-A upregulation and VEGFR/Akt activation are responsible for 
EV-induced EC migration.
To further confirm the involvement of miR-150 in VEGF-A mRNA regulation and Akt activation in ECs, we 
transfected HUVECs directly with premiR-150 or anti-miR-150 followed by VEGF-A mRNA, VEGF-A secre-
tion in medium and VEGF-A expression and Akt action in the cells within 3 hr post transfection. As shown in 
Fig. 7A, premiR-150 transfection significantly increased VEGF-A mRNA while anti-miR-150 transfection had no 
effect. ELISA analysis of VEGF-A in cell culture medium revealed a similar trend (Fig. 7B). Western blot analysis 
indicated that premiR-150 transfection increased both ErK and Akt phosphorylation, which was ablated by the 
presence of SU5416 (Fig. 7C). A significant increase was detected in VEGF band in the premiR-150 transfection 
sample, while elevated amount of VEGF could be detected in both control and premiR-150 transfection samples 
under SU5416 treatment (Fig. 7C). The results suggest that miR-150 can upregulate VEGF-A mRNA, secretion 
and its receptor-mediated Akt phosphorylation in ECs.
Discussion
The communication between ECs and SMCs is critical for the maintenance of vessel wall homeostasis and remod-
elling. Under physiological conditions, ECs and SMCs liaise with each other via paracrine and/or juxtacrine 
manner to control vessel tone31. The co-ordinations between ECs and SMCs on their proliferation and migration 
are essential for arteriogenesis32. Under pathological conditions, risk factors-induced endothelial dysfunction 
can trigger medial SMC proliferation and/or apoptosis, eventually leading to vascular disease development33,34. 
Multiple genes and factors have been found to be involved in the liaison of EC-SMC interaction. XBP1 plays 
diverse roles in ECs and SMCs. In ECs, under oxidative or ER stress, XBP1 splicing contributes to EC autophagic 
and apoptosis response26,27,35–37; while under growth factor stimulation, XBP1 splicing contributes to EC prolif-
eration23,24,38. In SMCs, XBP1s contributes to calponin h1 decrease, leading to SMC proliferation and neointima 
formation17,39. In this study, we demonstrate that XBP1 is also involved in the liaison between ECs and SMCs.
The compensative angiogenesis in ischemic tissue is essential for cell survival and tissue or organ function 
restoration. This is a multiple cells and factors-involved multi-step process, including existing ECs-mediated 
angiogenesis and stem/progenitor cell-mediated neovascularization. VEGF, PDGF and hypoxia inducible factor 
1 (HIF-1) are the main modulators of angiogenesis.
Several studies have shown that XBP1 promotes angiogenesis in cardiac hypertrophy via upregulating VEGF 
expression in ECs25,40–43. Our previous study revealed that XBP1 is a downstream of VEGF signalling path-
way mediator23. In this study, we found that XBP1 splicing in SMCs could upregulate VEGF-A expression and 
VEGF receptor-dependent Akt phosphorylation in ECs. The activation of Akt phosphorylation may be modu-
lated through VEGF via autocrine or paracrine mechanisms. The overall effect is to induce EC migration and 
angiogenesis. The key mediator for the XBP1/VEGF crosstalk-mediated EC-SMC liaison seems to be miR-150. 
MiRNAs are a set of small non-coding RNAs participating in multiple cellular processes including cell motility. 
Secretion and delivery of miRNAs via EVs contribute to intercellular communication44. It has been reported 
that miR-150 can be secreted from monocytes via EVs and increase EC migration and angiogenesis14,29,30. Our 
study demonstrated that miR-150 can be secreted from SMCs via EVs and increase VEGF-A expression and Akt 
phosphorylation in ECs. Very importantly, direct transfection of miR-150 into HUVECs can increase VEGF-A 
mRNA, VEGF secretion and Akt phosphorylation. These results suggest a positive role of miR-150 in VEGF-A 
signalling pathways and EC migration and angiogenesis. Different from miR-150 transfection-induced ErK 
Figure 5. XBP1s suppressed miR-150 transcription. (A) Over-expression of XBP1s suppressed miR-150 
promoter reporter gene expression. 0.1 μ g/well pSi-CHECK2-miR-150 (pSI-150) was co-transfected with 0.1 μ g/
well pShuttle2-XBP1s (pXBP1s) into HSMCs in triplicate. Renilla and Firefly luciferase activities were assessed 48 hr 
post-transfection. pSi-CHECK2 (pSI) and pShuttle2 (Mock) were included as control. (mean ± SEM, * P < 0.05; 
ANOVA, Dunnett post-test) (B) Exogenous premiR-150 suppressed miR-150 promoter reporter gene expression. 
0.1 μ g/well pSi-CHECK2-miR-150 (pSI-150) was co-transfected with 10 pmol/well premiR-150 into HSMCs 
in triplicate. Renilla and Firefly luciferase activities were assessed 48 hr post-transfection. pSi-CHECK2 (pSI) 
and premiR control (ctl) were included as control. Data presented are mean of three independent experiments. 
(mean ± SEM, * P < 0.05; ANOVA, Dunnett post-test).
www.nature.com/scientificreports/
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phosphorylation, SMC-derived EVs suppressed ErK phosphorylation in EC, which may be due to other inhib-
itory components within the EVs. This may also explain why EVs have no effect on EC proliferation. However, 
several reports have suggested that endothelial intrinsic miR-150 seems to play a negative role in EC migration 
and/or angiogenesis45–47. The discrepancy among these reports may be derived from different protocols. In our 
study, we assessed VEGF-A expression, secretion and VEGF-downstream signalling pathway activation within 
3 hours post transfection. A negative feedback may exist in a long term period.
PDGF is another important growth factor for angiogenesis under ischemia. It can be induced from ECs in 
response to ischemia or other stimulus48–50, which in turn activates medial SMCs proliferation and migration, lead-
ing to vessel wall remodelling51,52. During this process, XBP1 splicing plays an important role17. In the present study, 
we found that PDGF stimulated SMCs to secret miR-150-containing EVs in XBP1 splicing dependent manner, 
leading to EC migration. Therefore, we may speculate that PDGF functions as a liaison mediator from ECs to SMCs.
Figure 6. VEGF-PI3K/Akt pathway was responsible for Ad-XBP1s/HSMC-derived EVs-mediated EC 
migration. (A,B) Ad-XBP1s/HSMC-derived EVs increased VEGF-A mRNA and Akt phosphorylation in 
HUVECs. EVs were isolated from Ad-XBP1s/HSMC condition medium (CM), reconstituted in M199 medium 
supplemented with 5 μ g/ml insulin and 5 μ g/ml transferrin and applied to HUVECs for time indicated, 
followed by quantitative RT-PCR analysis of VEGF-A mRNA (A) or western blot analysis of ErK and Akt (S473) 
phosphorylation (B). (C,D) Anti-miR-150 abolished XBP1s/HSMC-derived EVs-mediated VEGF-A expression 
and Akt. EVs were isolated from control (ctl) or anti-miR-150 transfected with Ad-XBP1s-infected HSMCs CM, 
reconstituted and applied to HUVECs for 2 h, followed by VEGF-A mRNA (C) and Akt (S473) phosphorylation 
assays (D). (E) SU5416 ablated Ad-XBP1s/HSMC-derived EVs-induced Akt phosphorylation. HUVECs 
were treated with EVs isolated from Ad-XBP1s in the presence of 10 μ M SU5416 for 2 h, followed by Akt 
phosphorylation assay. (F) SU5416 and LY294002 attenuated Ad-XBP1s/HSMC-derived EVs-induced HUVEC 
migration. Transwell migration assays were performed with EVs isolated from Ad-XBP1s-infected HSMC CM in 
M199 medium supplemented with insulin and transferrin in the presence of SU5416 (SU) or 10 10 μ M LY294002 
(LY) for 8 h. Left panel shows the representative images of migrated cells while right panel shows average migrated 
cells per 10x view. Ad-null and DMSO (DM) were included as control. Data presented are representative images 
or mean of three independent experiments. (mean ± SEM, * P < 0.05, ** P < 0.01; ANOVA, Dunnett post-test).
www.nature.com/scientificreports/
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HIF-1 is a critical transcription factor, essential for cell survival and angiogenesis under ischemia. In response 
to hypoxia under ischemia conditions, HIF-1 upregulates the transcription of a set of genes that are involved in 
cell proliferation in both ECs and SMCs, contributing to revascularization in the ischemic tissues53. It has been 
reported that XBP1 can form a complex with HIF-1 in regulating gene transcription in cancer cells54. HIF-1 was 
reported to negatively regulate miR-150 expression during liver regeneration. In this study, we found that XBP1 
suppressed miR-150 transcription, in which HIF-1 might be involved. XBP1/HIF-1 complex may be responsible 
for the miR-150 downregulation in pulmonary airway SMCs under hypertension16. Further detailed investigation 
will be required to address the crosstalk between XBP1 and HIF-1 in both ECs and SMCs following ischemia.
Taken together, we may speculate that under ischemia the activated ECs secrete PDGF, which in turn acti-
vates XBP1 splicing in SMCs. The spliced XBP1 stabilizes miR-150 and increases miR-150 secretion via EVs. The 
miR-150-containing EVs are taken by ECs. The miR-150 upregulates VEGF-A mRNA and protein expression 
and secretion. VEGF activates Akt phosphorylation via an autocrine or paracrine mechanism, leading to ECs 
migration and angiogenesis (Fig. 8). Thus, PDGF, XBP1 splicing, miR-150 and VEGF form an important signaling 
pathway to liaise EC-SMC interaction, in which XBP1 splicing plays a central role and HIF-1 may be also involved 
through interaction with XBP1.
So far, we have demonstrated that XBP1 splicing is involved in EC and SMC proliferation and their interac-
tion, similar to many other important molecules, like PDGF, HIF-1. This will require us to make critical thinking 
when we intend to develop therapeutic strategies to intervene human diseases. For example, if we want to target 
XBP1 splicing in SMCs to suppress airway SMC proliferation under pulmonary hypertension, it may affect the 
EC-SMC interaction and EC proliferation as well. So, a cell specific targeting strategy will be required.
Methods
Chemicals and Reagents. All cell culture serum and media were purchased from Thermo Fisher Scientific, 
while cell culture supplements were purchased from Sigma. Rat anti-CD31 (553369) was purchased from 
Pharmingen while antibodies against alpha SMA (ab7817), phosphor-ErK (ab50011) and ErK1/2 (ab17942) were 
from Abcam. The antibodies against phospho-Akt (sc-7985R), Akt1 (sc-1619) and GAPDH (sc-25778) were from 
Santa CruZ Biotech. The antibody against VEGF (SAB1402390) was from Sigma. All secondary antibodies were 
from Dakocytomation. All microRNA reagents were purchased from Thermo Fisher Scientific. PDGF, insulin, 
holo-transferrin, SU5416, LY294002, DMSO, DAPI and Giemsa were purchased from Sigma.
Cell culture. Human aortic smooth muscle cells (HSMC, ATCC-PCS-100-012) were purchased from ATCC 
and cultured on 0.04% gelatin-coated flasks in DMEM medium supplemented with 10% fetal bovine serum 
(FBS), 100 U/ml penicillin and streptomycin in humidified incubator supplemented with 5% CO2. The cells were 
split every three days at a ratio of 1:3. Human umbilical vein ECs (HUVECs, ATCC-PCS-100-010) were cultured 
on 0.04% gelatin-coated flasks in M199 medium supplemented with 1 ng/ml β -EC growth factor, 3 μ g/ml EC 
Growth Supplement from bovine neural tissue, 10 μ /ml heparin, 1.25 μ g/ml thymidine, 10% FBS, 100 μ /ml peni-
cillin and streptomycin in humidified incubator supplemented with 5% CO2. The cells were split every three days 
Figure 7. Over-expression of premiR-150 increased VEGF-A expression and VEGF receptor dependent 
Akt phosphorylation in HUVECs. (A,B) Over-expression of premiR-150 increased VEGF-A expression and 
secretion. HUVECs were transfected with premiR-150 or anti-miR-150 in serum free M199 medium for 5 h, 
then treated with M199 medium supplemented with 5 μ g/ml insulin and 5 μ g/ml transferrin for 3 h, followed by 
quantitative RT-PCR analysis of VEGF-A mRNA (A) or ELISA assay to detect VEGF-A in cell culture medium 
(B) premiR and anti-miR control RNA fragments were included as controls. (C) SU5416 ablated premiR-
150-induced Akt and ErK phosphorylation. HUVECs were transfected with premiR-150 or anti-miR-150 in 
serum free M199 medium for 5 h, then treated with M199 medium supplemented with 5 μ g/ml insulin and 
5 μ g/ml transferrin in the presence of 10 μ M SU5416 for 3 h, followed by Western blot analysis of Akt and 
ErK phosphorylation and VEGF expression. premiR RNA fragments DMSO were included as controls. Data 
presented are representative images or mean of three independent experiments. (mean ± SEM, * P < 0.05; 
ANOVA, Dunnett post-test).
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at a ratio of 1:5. Both HSMCs and HUVECs up to passage 10 were used in this study. HEK293 and HEK293T cells 
were maintained in DMEM supplemented with 10% FBS and penicillin/streptomycin and were split every three 
days at a ratio of 1:4.
Adenoviral and shRNA lentiviral infection. For adenoviral infection, HSMCs were incubated with 
Ad-null, or Ad-XBP1u(unspliced XBP1) or Ad-XBP1s(spliced XBP1) virus at 10 MOI for 6 hr, and then cultured 
in fresh complete growth medium for time duration indicated in figure legends. For shRNA lentiviral infection, 
HSMCs were incubated with 100 transfection unit/cell of non-target shRNA or XBP1 shRNA or IRE1α shRNA 
lentivirus in the presence of 10 mg/mL polybrene for 16 hr, followed by culture in fresh complete growth medium 
for 72 hr and subjected to further treatments.
Cell counting. HUVECs were seeded in complete growth medium at a 1 × 105 cells/well in 6-well plates for 
24 hr. The medium was changed to M199 supplemented with 0.5% FBS (control)-based conditioned medium 
from the Ad-XBP1s infected SMCs and incubated for 24 hr. Upon harvest, the cells were trypsinized to single cell 
suspension and subjected to cell counting using a multisizer 3 coulter counter (Beckman Coulter), according to 
the manufacturer’s instructions.
Wound healing migration assay. Wound was created by scratching confluent HUVECs in 6-well plates. 
After removal of the cell debris and medium, fresh conditioned medium was added and incubated for 6 hr. Three 
scratching lines were created in each well, and each conditioned medium was performed in three wells. Images 
were taken with at three different sites on each scratching line at 0 hr and 6 hr. The average migrated cells were 
calculated from 3 sites/line x 3 lines/well x3 wells.
Transwell migration assay. The HUVECs were detached by using trypsin and resuspended in M199 
containing 0.5% FBS. A 100 μ l of 5 × 105 cells/ml cell suspension was added into the insert and 600 μ l of M199 
containing 0.5% FBS or conditioned medium or reconstituted EVs was added into the holder of the transwell 
(8 μ m pore size), followed by incubation for 6 hr. The cells were then fixed with methanol/acetic acid (3:1) for 
15 minutes, and stained with Giemsa solution (Sigma) for 15 minutes. After removal of the cells inside the 
insert, the migrated cells were observed under Nikon Eclipse TS100 microscope and images were taken by 
Nikon Digital Sight system and processed with Adobe Photoshop software. Cells were calculated from 3 10x 
view/well x 3 wells.
Tube formation assay. The effect of EVs on EC angiogenesis was assessed by tube formation assay as 
described previously55. Briefly, 50 μ l/well of growth factor-reduced Matrigel solution (Millipore) was added to 
96-well plate and solidified at 37 °C. EVs were isolated from anti-miR-150 or control miR-transfected Ad-null or 
Ad-XBP1s-infected HSMCs and reconstituted in M199 medium supplemented with 5 μ g/ml insulin (Sigma) and 
5 μ g/ml transferrin (Sigma). 3000 HUVECs were resuspended in 100 ul EV-reconstituted medium and added to 
matrigel containing wells in triplicate and incubated in 37 °C humidified incubator supplemented with 5% CO2 
Figure 8. A schematic illustration of PDGF-IRE1α-XBP1-miR-150 pathway in EC-SMC interaction. Under 
ischemia, the activated ECs may secret PDGF, which in turn activates IRE1α phosphorylation, leading to XBP1 
mRNA splicing to remove 26-nucleotide intron in SMCs. The spliced XBP1 stabilizes miR-150 and increases its 
secretion via extracellular vesicles (EVs). The miR-150-containing EVs are taken by ECs, increasing VEGF-A 
mRNA transcription or stability, leading to VEGF-A protein production and secretion. VEGF-A triggers the 
ErK and Akt phosphorylation via binding to VEGF receptor in an autocrine or paracrine manner. The activated 
Akt contributes to EC migration, leading to angiogenesis.
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for 4 h. Tube formation was observed under Nikon Eclipse TS100 microscope and images were taken by Nikon 
Digital Sight system and processed with Adobe Photoshop software. Cells were calculated from 3 10x view/well 
x 3 wells.
EVs isolation. The EVs were isolated from SMCs culture supernatants by differential centrifugations as pre-
viously described56. Briefly, the conditioned medium was collected from Ad-XBP1s-infected or PDGF-BB treated 
SMCs and centrifuged at 500 g (Sorvall Legend RT,75006445 swing-out rotor) at 4 °C for 5 min to remove cell 
debris. The supernatant was collected and centrifuged again at 4500 g at 4 °C for 30 min to remove smaller debris. 
The supernatant was then transferred to Ultra-Clear™ tube (Beckman coulter, Item No: 344059) and ultracen-
trifuged at 120000 g (Hitachi CP100NX,TH-641 rotor) at 4 °C for 60 min. Pellets were resuspended and washed 
in 1 ml of cold PBS and ultracentrifuged again at the same condition. The EVs pellets were subjected to miRNAs 
isolation and quantitative RT-PCR analysis for miR-150 or reconstituted into the original volume with M199 
medium containing 0.5% FBS (Figs 2–4 except Fig. 3E) or M199 medium supplemented with 5 μ g/ml insulin 
(Sigma) and 5 μ g/ml transferrin (Sigma) (Figs 3E, 6 and 7) for cellular function assays.
MicroRNA analysis. The cellular total RNA was isolated with mirVana™ miRNA isolation kit accord-
ing to the manufacturer’s instruction. The reverse transcription of miRNAs was performed with the Applied 
Biosystems® TaqMan® MicroRNA Reverse Transcription kit and Applied Biosystems® 5x RT primer. The quan-
titative PCR amplifications of samples were done via Applied Biosystems® TaqMan® Universal PCR Master Mix, 
No AmpErase® UNG and 20x TaqMan small RNA Assay with protocol provided.
VEGF-A mRNA analysis. The cellular total RNA was isolated with Qiagen RNeasy kit with protocol 
provided. One microgram of RNA was reverse transcribed into cDNA using Impro-RT transcription system 
(Promega) and 20 ng cDNA (relative to RNA amount) was amplified by a real time PCR SYBR master mix 
(Applied Biosystems) with a primer set of 5′ > ctg tct tgg gtg cat tgg agc < 3′ and 5′ > ctg cat ggt gat gtt gga ctc < 3′ 
for VEGF-A. The 18s rRNA primer set of 5′ > ata cat gcc gac ggg cgc tg < 3′ and 5′ > gga gag ggg ctg acc ggg tt < 3′ 
was included as internal control. The fold of induction was defined as ct for VEGF-A minus ct for 18s rRNA with 
that of control group set as 1.0.
Plasmid construction and transient transfection. The 1.1 kb fragment of miR-150 promoter region 
was amplified by PCR using a primer set of 5′ > gcg cag atc tat tca ctt aat taa aga caa aga g < 3′ and 5′ > tat atc 
tag agc cgc cgc tgc cgc tgc tgc ctc g < 3′ and inserted into the BglII/NheI sites of pSi-CHECK2 to replace the 
SV40 early enhancer promoter, designated as pSI-150. The plasmid was verified by DNA sequencing. For tran-
sient transfection assay, HSMCs were seeded in 12-well plates at 5 × 104 cells/well in triplicate 24 hr prior to 
transfection. Medium was changed to serum and antibiotics free DMEM. 0.1 μ g/well reporter plasmid DNA 
(pSi-CHECK2 or pSI-150) and 0.1 μ g/well pShuttle2-XBP1s or 10 pmol premiR-150 were transfected into HSMCs 
with 1 μ l lipofectamine RNAiMax (Thermo Fisher Scientific) according to the procedure provided. Five hours 
later, the transfection solution was removed and fresh complete growth medium was added and the cells were 
incubated for 24 hr, followed by luciferase activity assay with the dual reporter system (Promega) according to 
the protocols provided. The relative luciferase activity was defined as the ratio of readout for Renilla luciferase to 
that for Firefly luciferase with that of control group set as 1.0. For the knockdown of endogenous miR-150, HSMC 
were transfected by 50 pmol/25 ml flask anti-miR-150 (hsa-miR-150-5p inhibitor, Sigma) with lipofectamine 
RNAiMax (Thermo Fisher Scientific) according to the procedure provided.
ELISA analysis of VEGF. HUVECs were transfected with premiR control, premiR-150, anit-miR control or 
anti-miR-150 in serum free M199 medium for 5 h, followed by incubation with M199 medium supplemented 
with 5 μ g/ml of insulin and 5 μ g/ml of transferrin for 3 h. The medium was collected and cell debris was removed 
by centrifugation at 2000 rpm at 4 °C for 5 min. The medium was then concentrated 20 fold using Ultracel-10 K 
centrifuge unit (Millipore) and subjected to VEGF concentration assessment using VEGF human ELISA Kit 
(ab100663, Abcam) with protocol provided. The fold of induction was defined as the relative A450 nm absorbance 
with that of premiR control group set as 1.0.
Western blot analysis. Western blot analysis was performed according to standard procedures described 
elsewhere. Briefly, the cells were lysed with IP-A buffer [10 mM Tris-HCl, pH7.5, 120 mM NaCl, 1 mML EDTA, 
1% Triton X-100 plus protease inhibitor cocktail tablets (one tablet for 50 mL, Roche)] and the protein concentra-
tion was measured by BioRad protein assay ( BioRad)). 50 μ g lysate was applied to SDS-PAGE, PVDF membrane 
(Amersham) transfer, blocking with 5% milk powder in TBST buffer (10 mM Tris-HCl, pH7.5, 120 mM NaCl, 
1 mM EDTA, 0.05% Tween-20), primary and secondary antibodies incubation, ECL development and X-ray film 
exposure (Amersham). The images were processed by Adobe Photoshop software.
Hindlimb ischemia. The XBP1LoxP/LoxP(regarded as wild type, WT), and SM22Cre/XBP1loxP/loxP ( SMC condi-
tional knockout, XBP1smcko) mice were created as described previously17 and were anaesthetized using a com-
bination of Hypnorm (25 mg/kg; Veta Pharma, UK) and Hypnovel (25 mg/kg; Roche). The right femoral artery 
was ligated permanently, i.e. the femoral artery was ligated at two adjacent sites with the middle part cut23. The 
foot blood flow was measured with LDI Doppler laser scanner (Moor Instruments) 30 minutes post-surgery, 
1 week and 2 weeks post-surgery. The reperfusion percentage was defined as the ratio of mean measurement 
in the foot area of ligated hindlimb to that of contralateral unligated hindlimb. The data was processed with 
Microsoft Excel software. The flow image was processed with Adobe Photoshop software. The mice were sac-
rificed humanely after flow measurement at 2 weeks post-surgery. Adductor muscle tissues of ligated side were 
harvested and cryo-sectioned, followed by immunofluorescent staining with anti-CD31 and smooth muscle 
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actin antibodies. All animal experiments in this study were performed according to protocols approved by the 
Institutional Committee for Use and Care of Laboratory Animals.
Indirect immunofluorescence staining. Immunofluorescence staining was performed according to 
standard procedure57. Briefly, the mouse skeletal muscle cryo-sections were air dried at room temperature and 
fixed with cold methanol (4 °C) for 15 min. The fixed sections were permeabilized with 0.1% Triton X-100 at RT 
for 15 min, followed by blocking with diluted swine serum (1:20) for 1 hr, incubation with diluted primary anti-
bodies for 1 hr and with secondary antibodies for 45 min. Nucleus was counterstained with DAPI. Images were 
taken by using SP5 confocal microscope (Leica, Germany), and were processed by Adobe Photoshop software. 
Magnification was indicated in figure legends as scale bars.
Statistical analysis. Data were expressed as the mean ± SEM and analyzed using GraphPad Prism 5 soft-
ware with t-test for pair-wise comparisons or analysis of variance (ANOVA) and significance was depicted by 
asterisks, * p < 0.05, * * p < 0.01.
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